Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Norwegian biopharmaceutical company BerGenBio has started Phase 1 trial of first-in- Class AXL receptor tyrosine kinase inhibitor, BGB324, to treat aggressive and metastatic cancers.
Subscribe to our email newsletter
The single ascending dose study will assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of BGB324.
BerGenBio CEO Richard Godfrey said the Phase 1 trial of BGB324 will evaluate the safety of BGB324 and clinical biomarker and pharmacodynamic assays the company has also developed.
"Our extensive preclinical data suggest that BGB324 has wide therapeutic potential to address a range of clinically challenging cancers and the growing problem of acquired drug-resistance," Godfrey said.
BGB324 selectively blocks the epithelial-mesenchymal transition that is believed to drive metastasis and drug-resistance.